Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO

Executive Summary

Shortly after the market closed on June 30, Biogen Idec and Exelixis confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos taking the helm of the Big Biotech July 15

Related Content

Scangos Leaves Biogen Transformed And Transitioning
Spotlight Returns To Biogen R&D To Sustain Success
Biogen Sets Aside Cash For Business Development, Expects New Launches In 2014
Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
Gilenia's Risk Management Should Key On Initial Doctor Visit, Cmte. Says
Agreement Averts Another Proxy Fight Between Biogen Idec, Icahn
GSK/Exelixis: The End of an Era
Takeda/ Millennium: The Price is Right
Takeda/ Millennium: The Price is Right





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts